Final NHS green light for Roche’s Kadcyla
The drug will be funded as an option for treating patients with HER2-positive early breast cancer
Read More
Tag: Kadycla
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
